13 Jinhua (attached list)

Basically, the stocks in this sector have good fundamentals, stable returns and low valuations. Basically, they all have the background of state-owned assets or local governments. Drinking and taking medicine has always been favored by big funds, and it is the first choice for big funds to hold groups. There are many stocks in the sector, and the moat threshold is extremely high. Some stock products are state core secrets.

The overall market of the plate is moderate, with distinct levels, and the proportion of high, medium and low (market value and stock price) stocks is balanced.

In recent years, with the support of the state and strong policy support (tax reduction and exemption, comprehensive income increase and favorable policies), the long-term income growth of some stocks is expected to be obvious. Details are as follows:

1, Rheinland Bio (Guilin, Guangxi), major shareholder: Qin Benjun.

Total market value: 531300 million, circulation market 4.324 billion, third quarter of 20265438+0.0.150.

Annual line 202 1, opening: 8.37, closing: 9.7 1, turnover rate: 5 14.86%.

In 2022, the line opened at 9.7 1 and closed at 10.34, with a turnover rate of 5 1.09%.

Main business: production of high-purity monomers and standardized extracts of plant functional components such as mogrosides, procyanidins, anthocyanins and Lycium barbarum polysaccharides.

Business scope: R&D, production, sales, technology transfer and self-import and export of plant extracts, traditional Chinese medicine extracts, food and food additives, feed and feed additives, plant extract formula products, skin care cosmetics and personal care products; Research, application, popularization and technology transfer of plant seedling and breeding.

2. Taiji Group (Chongqing), major shareholder: Taiji Group Co., Ltd.

Total market value:11900 million, circulation market11900 million, 202 1 third quarter: 0.450.

Annual line 202 1, opening: 13.26, closing: 22.46, turnover rate: 353.67%.

In 2022, the annual line opened at 24.7 1 and closed at 23.39, with a turnover rate of 82.59%.

Main business: production and sales of Chinese patent medicine, western medicine, health care products, medical packaging products and medical devices, and import and export of raw materials, Chinese herbal medicines and medical packaging.

Scope of business: processing and sales: Chinese patent medicine and western medicine; Planting and marketing of Chinese herbal medicines; Drug retail and wholesale; Agricultural and sideline products; Non-staple food and other food sales, secondary maintenance of automobiles and the following operations, packaging and decoration, other printing and accommodation; Processing and sales of health care products; Medical device sales; Processing of pharmaceutical packaging products; Sales of department stores, hardware, electrical materials, chemicals, handicrafts, machinery and equipment, and building materials (excluding dangerous chemicals and wood); Machining of mechanical parts; Aquaculture; Commodity packaging; Tourism development; Real estate development; Own houses and leased land; Trade brokers and agents.

3. Baiyi Pharmaceutical (Guiyang, Guizhou), major shareholder: Dou Qiling.

Total market value: 61.300 million, circulation market 61.300 million, and 5438+0: 0.380 in the third quarter of 2026.

Annual line 202 1, opening: 5.09, closing: 8. 13, turnover rate: 47 1.07%.

Line 2022, opening: 8.25, closing: 8.22, turnover rate: 58.06%.

Main business: production and sales of traditional Chinese medicine products

Business scope: tablets, granules, syrups, freeze-dried powder injections, mixtures, dripping pills, decoction, tincture and oral liquid. Xinyi Factory, Pingba County, Anshun City, Guizhou Province: extraction of traditional Chinese medicine; The export business of self-produced products and related technologies of this enterprise and its member enterprises; Engaged in the import business of raw and auxiliary materials, machinery and equipment, instruments and meters, spare parts and related technologies required by the production and scientific research of this enterprise and its member enterprises; Manage the feed processing and "three to one supplement" business of this enterprise; Chinese herbal medicine planting and breeding project investment; Agricultural product sales; Chinese herbal medicine market information consulting service

4. Tong Ren Tang (Beijing), major shareholder: Beijing Tong Ren Tang (Group) Co., Ltd.

Total market value: 65.7 billion, circulation market 65.7 billion, 20265438 third quarter +0: 0.670.

Annual line 202 1, opening: 39.94, closing: 44.98, turnover rate: 373.60%.

Line 2022, opening: 49.00, closing: 48.98, turnover rate: 29. 12%.

Main business: production, scientific research and sales of traditional Chinese medicine.

Business scope: processing and manufacturing large-capacity injections, small-capacity injections, freeze-dried powder injections, tablets, hard capsules, soft capsules, granules, mouthwashes, aerosols, APIs, psychotropic drugs, small-capacity injections, paints, gels, packaging of imported drugs, extraction of traditional Chinese medicines, and pharmaceutical machinery and equipment; Sales company's self-produced products, machinery and electrical equipment; Technology development, technology transfer and technical services; Self-management and agency of import and export business of various commodities and technologies; Operating feed processing and "three to one supplement" business; Operating counter-trade and entrepot trade.

5. Panlong Pharmaceutical (Shaanxi Xi), major shareholder: Xie Xiaolin.

Total market value: 263 1 100 million, circulation market 65.438+67.9 million, 20265438 third quarter +0: 0.850.

Annual line 202 1, opening: 29.76, closing: 3 1.33, turnover rate: 533.69%.

In 2022, the annual line opened at 32.50 and closed at 3 1.80, with a turnover rate of 79.07%.

Main business: R&D, production and sales of Chinese patent medicines, with Panlongqi tablets as the leading product and orthopedic rheumatism as the main treatment field, covering hepatobiliary, cardiovascular and cerebrovascular diseases, gynecology, anti-tumor and other treatment fields.

Scope: medical research and experimental development; Sales of sanitary products and disposable medical products; Disinfectant sales; Acquisition of Chinese herbal medicines; Sales of second-class medical devices; Sales of first-class medical devices; Class I medical device production; Cosmetics retail. Licensed items: drug import and export; Technology import and export; Import and export agent; Pharmaceutical production; Disinfectant production; Production of sanitary products and disposable medical products; Commissioned the production of drugs; Import and export of goods; Production of disinfection equipment; Drug retail; Road freight transport; The second kind of medical device production; Production of the third kind of medical devices; The third kind of medical device management; Cosmetic production; Production of health products; Sales of health products; Health food production; Health food sales; Food production; Food management; Production of formula food for special medical use; Sales of formula food for special medical use; Food internet sales

6. Jiang Zhong Pharmaceutical (Nanchang, Jiangxi), major shareholder: China Resources Jiang Zhong Pharmaceutical Group Co., Ltd.

Total market value: 8.587 billion, circulation market 8.509 billion, 20265438 third quarter +0: 0.720.

Annual line 202 1, opening: 13.26, closing: 14.45, turnover rate: 462.438+07%.

In 2022, the line opened 15.20 and closed 14.25, with a turnover rate of 35. 17%.

Main business: engaged in the production, research and development and sales of drugs and health care products.

Scope of business: production and sales of Chinese patent medicines and chemical medicines; Production and sales of common foods such as sugar, chocolate, candy and drinks; Production and sales of special foods such as health foods and foods for special medical purposes; Production and sales of medical devices; Production and sales of sanitary products such as sanitary wipes; Acquisition of agricultural and sideline products; Domestic trade and production and processing, international trade; R&D services, technology transfer services and technical consulting services.

7. China Resources Shuanghe (Beijing), major shareholder: Beijing Pharmaceutical Group Co., Ltd.

Total market value:1400 million, circulation market1400 million, third quarter of 20265438 +0: 0.852.

Annual line 202 1, opening:13.1,closing: 13.37, turnover rate: 124.23%.

In 2022, the annual line opened at 13.69 and closed at 13.58, and the turnover rate was 12.87%.

Main business: processing, manufacturing and selling preparations and medicines, chemical raw materials and pharmaceutical equipment.

Business scope: processing and manufacturing large-capacity injections, small-capacity injections, freeze-dried powder injections, tablets, hard capsules, granules, mouthwashes, soft capsules, aerosols, gels, paints and imported drugs, and packaging them separately; ; Sales company's self-produced products, machinery and electrical equipment; Technology development, technology transfer and technical services; Production of pharmaceutical machinery and equipment.

8. Shuanglu Pharmaceutical (Beijing), major shareholder: Xinxiang Bailu Investment Group Co., Ltd.

Total market value:11400 million, circulation market 9.408 billion, 20021third quarter: 0.424.

Annual line 202 1, opening: 10.00, closing: 10.8 1, turnover rate: 350. 17%.

In 2022, the opening price 10.92, the closing price 1 1.2 1, and the turnover rate 17.9 1%.

Main business: R&D, production and operation of genetic engineering drugs and biochemical drugs, including R&D, production and operation of genetic engineering, biochemical drugs, chemical raw materials and preparations.

Business scope: production of tablets, hard capsules, granules, soft capsules, dripping pills, freeze-dried powder injections, powder injections, large-capacity injections, small-capacity injections, gels, eye drops, nasal sprays, bioengineering products (recombinant human basic fibroblast growth factor for external use, recombinant human granulocyte stimulating factor injection, recombinant human interleukin-2 for injection (125ala), recombinant human interleukin-2 for injection (/ Kloc-0/25 Ala), recombinant human interleukin-1 1 for injection, recombinant adenosylmethionine succinate, tropisetron hydrochloride, telmisartan, disodium cytidine triphosphate, enoxaparin sodium, naloxone hydrochloride, glycyl -L- tyrosine, glycyl -L- glutamine and pamidronate disodium. Production and sale of "Shuanglu Hong Xin Capsule" health food.

9. Kunyao Group (Nanjing, Jiangsu), major shareholder: Huali Pharmaceutical Group Co., Ltd.

Total market value: 8.856 billion, circulation market 8.827 billion, and +0: 0.572 in the third quarter of 20265438.

Annual line 202 1, opening: 8.43, closing: 1 1.05, turnover rate: 333.66%.

In 2022, the annual line opened 1 1.32 and closed 12.06, with a turnover rate of 65.26%.

Main business: engaged in drug research and development, manufacturing and sales.

Business scope: Chinese and Western raw materials and preparations, chemical raw materials, intermediates, reagents, packaging materials, extracts and Chinese herbal pieces, agricultural and sideline products and Chinese herbal medicines, industrial hemp planting, research and development, mosaic processing, domestic trade, material supply and marketing, import and export of goods and technologies, scientific and technological development, consulting services, mechanical processing, pharmaceutical equipment manufacturing, installation and maintenance, medical engineering design, procurement, production and sales of medical devices.

10, Yunnan Baiyao (Kunming, Yunnan), major shareholder: Yunnan State-owned Equity Operation Management Co., Ltd.

Total market value:133.9 billion, circulation market 63.2 billion, third quarter of 20265438 +0: 1.920.

Annual line 202 1, opening: 102.34, closing: 104.05, turnover rate: 3 15.06%.

In 2022, the annual line opened 104.99 and closed 105.99, and the turnover rate was 15.52%.

Main business: research, production and sales of chemical raw materials, chemical preparations, Chinese patent medicines, Chinese herbal medicines, biological products, health foods, foods, cosmetics and beverages; Wholesale, retail, purchase and sale of sugar, tea, building materials and decorative materials; Science and technology and economic and technical consulting services, property management, medical equipment, daily chemical products, outdoor products.

Scope: production and sales; Sales of rubber paste, paste, disinfection products, electronic and digital products; Information technology, science and technology and economic and technical consulting services; Import and export of goods; Property management.

1 1, Guizhou Bailing (Anshun, Guizhou), major shareholder: Jiang Wei.

Total market value: 654.38+002 billion, circulation market 6.767 billion, and +0: 0.090 in the third quarter of 2026.5438.

Annual line 202 1, opening: 7.80, closing: 7.60, turnover rate: 425.85%.

In 2022, the annual line opened at 7.58 and closed at 7.44, with a turnover rate of 54.77%.

Main business: production and sales of Chinese patent medicines mainly based on Miao medicines. Mainly engaged in the production and sales of cough-relieving and phlegm-resolving drugs, cold medicines, cardiovascular and cerebrovascular series of Chinese patent medicines, as well as the research and development of other natural and chemical drugs.

Business scope: tablets, capsules, syrups, soft capsules, granules, pills, powders, sprays, decoctions, tinctures, dropping pills, bulk drugs and large injections; Production and sales in prepackaged foods; Production of sanitary products; Production and processing of health food; Production of candy products; Chinese herbal medicine cultivation; Marketing planning; Design, produce, publish and represent all kinds of advertisements at home and abroad; Marketing promotion; Market research and research; Cultural and academic exchanges and marketing management; Cosmetic sales; Lease its own warehouse and supporting equipment; Production and sales of disinfectants; Production and sale of sanitary products.

12, People Tongtai (Harbin, Heilongjiang), major shareholder: Harbin Pharmaceutical Group Co., Ltd.

Total market value: 3.966 billion, circulation market 3.966 billion, and +0: 0.404 in the third quarter of 20265438.

Annual line 202 1, opening: 6.77, closing: 6.72, turnover rate: 106.65%.

In 2022, the annual line opened at 6.80 and closed at 7.0 1, with a turnover rate of 9.94%.

Main business: pharmaceutical manufacturing, pharmaceutical distribution and investment management.

Scope: investment management and consulting; Investment and investment management in the medical industry with its own assets; Medical consulting services; Enterprise management consulting; Accept the entrustment and engage in the asset management and enterprise management of the entrusting party.

13, Dong 'e Ejiao (Liaocheng, Shandong), major shareholder: China Resources Dong 'e Ejiao Co., Ltd.

Total market value: 26.8 billion, circulation market 26.8 billion, 20265438 third quarter +0: 0.470.

Annual line 202 1, opening: 45.03, closing: 48.75, turnover rate: 300.78%.

In 2022, the line opened at 49. 12 and closed at 4 1.88, with a turnover rate of 24.0 1%.

Main business: production and operation of Chinese patent medicines, biopharmaceuticals, health foods, pharmaceutical excipients, medical devices, packaging and printing, etc.

Business scope: industrial investment and equity investment; Production and sales of traditional Chinese medicine mixture, adhesive, decoction, granule, hard capsule and oral liquid; Livestock breeding, acquisition, slaughter, processing and sales; Planting, production, acquisition, processing and sales of Chinese herbal medicines; Commodity import and export business within the approved scope; Sales of chemical products; Producing and selling health food within the permitted scope; Entrusted to produce and sell health food; Food within the scope of production, processing and sales license; Production and sale of plastic packaging, containers, tools and other products for food within the scope of the license; Investment, lease, transfer and income of self-owned assets; Direct sales of approved products in approved areas. Production and sales of cosmetics, health care devices, medical devices, small kitchen utensils, cleaning supplies and household appliances; Health consultation and services, tourism and sightseeing services, conference, exhibition and reception services, arts and crafts sales.

Do not make recommendations or suggestions, investment is risky, and you need to be cautious when entering the market.